Home/Innovation Pharmaceuticals/Barry Schechter, MD, FAAO

BS

Barry Schechter, MD, FAAO

Independent Board Member

Innovation Pharmaceuticals

Therapeutic Areas

Infectious Diseases Oncology Supportive Care Inflammatory Bowel Disease Dermatology

Innovation Pharmaceuticals Pipeline

Drug	Indication	Phase
Brilacidin (IV)	Acute Bacterial Skin and Skin Structure Infection (ABSSSI)	Phase 2b
Brilacidin (Oral Rinse)	Oral Mucositis in Head & Neck Cancer (Prevention)	Phase 2
Brilacidin (Enema)	Ulcerative Proctitis/Proctosigmoiditis (IBD)	Phase 2
Brilacidin	Hard-to-Treat Fungal Diseases	Preclinical
BEAMED	Image-Guided Surgical Laser (Oncology, Neurology)	Discovery

Leadership Team at Innovation Pharmaceuticals

Chief Executive Officer, Chief Financial Officer, Board Chairman

Senior Vice President, Clinical Sciences and Portfolio Management

Zorik Spektor, MD, FAAP

Independent Board Member

View full Innovation Pharmaceuticals profile